FDA Approves Risankizumab, Adds Stronger Warning to Sleep Medications
FDA Issues Boxed Warning for Febuxostat & Approves Colchicine for Gout Flare
Safety Risk with Higher Dose Tofacitnib
FDA Update: Priority Review for Non-Opioid Treatment & New Warning for Fluoroquinolones
The Perils of Pain Meds Revisited
Phase 2 Results for Mavrilimumab Are In
Turmeric: The Evidence for Therapeutic Use for Arthritis
FDA Issues Safety Warning
HCQ Debate: Should Dose Be No More Than 5 mg/kg in All SLE Patients?
- 1
- 2
- 3
- …
- 17
- Next Page »